CRISPR screen unveils enzyme target for inflammatory diseases
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
List view / Grid view
Genomics is the branch of molecular biology concerned with the structure, function, evolution, and mapping of genomes.
Scientists used a CRISPR-based screen to find that inhibiting MTHFD2 reduces disease severity in inflammatory disease models.
The antihypertensive drug candesartan cilexetil reduced matrisomal protein accumulation in mice with cerebral small vessel disease.
Scientists reveal that higher levels of inflammatory chemicals involved in fat metabolism occur in people with amyotrophic lateral sclerosis.
The study paves the way for the construction of complex nanoscale computers for the prevention and treatment of cancer and other diseases.
The UTX gene mutation was found to lead to an increased cancer risk, presenting a potential drug target for preventative therapies.
The intestine chip was infected with a coronavirus to test a variety of drugs, presenting a new method to investigate COVID-19 treatments.
The study used CRISPR to show that DNA “de-methylation” activity can be targeted to anywhere in the DNA and may be a new therapeutic strategy.
Researchers discovered that cardiovascular damage was caused by reduced microRNA-210 levels in patient cells and mice with type 2 diabetes.
The study found that deleting the ABI3 gene in mice increased plaques and inflammation in the brain, suggesting avenues for new treatments.
Scientists discover a long noncoding RNA, termed NXTAR, and a small molecule drug that could be used to treat prostate cancer.
Scientists utilised CRISPR technology and deep learning systems to investigate the genes associated with polycystic kidney disease.
Researchers used obese fruit flies to analyse how gene activities affect triacylglyceride levels, unveiling novel drug targets for obesity.
The peptide-centric chimeric antigen receptors killed neuroblastoma cells in mice and could potentially expand the pool of immunotherapeutic targets.
The gene therapy restored the ability of neurons to convert levodopa to dopamine and may help develop therapies to slow disease progression.
Moderna and Metagenomi have announced a collaboration to jointly create next-generation in vivo gene editing therapeutics.